Visterra raises $30m for infectious disease pipeline
This article was originally published in Scrip
Visterra raised a $30m Series B round from new and existing venture capital investors to fund clinical development of the company's pipeline of novel monoclonal antibodies to prevent and treat infectious diseases.
You may also be interested in...
AnaptysBio, Jounce and ObsEva were the first three companies to go public in 2017 – all in January – while no therapeutics firms went public in January 2016. The difference? Better US biopharma stock performance.
While Phase III results for Eisai and Biogen’s lecanemab show amyloid clearance provides benefit and Roche’s Phase III gantenerumab data are supportive, more data and certainty of access to treatment are needed.
Lilly’s donanemab showed faster, deeper amyloid clearance versus Biogen/Eisai’s Aduhelm and Roche’s failed Phase III gantenerumab studies showed the importance of deep, rapid removal.